ANDA 90955, held by Teva Pharmaceuticals. Montelukast Sodium.
As of Nov 21, 2026, ANDA 90955 (Montelukast Sodium), held by Teva Pharmaceuticals, was first approved by FDA on Aug 3, 2012, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Montelukast SodiumEQ 4MG BASE/PACKET · granule;oral | Montelukast Sodium | Discontinued |
| Oct 4, 2023 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 4, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| Nov 8, 2019 | Supplement 13Labeling · Standard review | Approved | None posted |
| Nov 8, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Nov 8, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 28, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 28, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 26, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 6, 2013 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 17, 2012 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 3, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters